Core Viewpoint - SciSparc Ltd. is strategically expanding its operations by acquiring endoscopy intellectual property from Xylo Technologies Ltd., moving beyond its core neuroscience pipeline into medical device commercialization [1]. Strategic IP Acquisition - SciSparc has signed a binding term sheet to acquire a portfolio of patents, trademarks, and know-how related to advanced endoscopic imaging systems, focusing on the MUSE platform, a single-use device for transoral fundoplication procedures aimed at treating gastroesophageal reflux disease (GERD) [2]. Expansion into Procedural Technology - Through its majority-held subsidiary NeuroThera Labs Inc., SciSparc has primarily focused on clinical-stage therapies. The acquisition broadens its exposure into procedural technology for gastrointestinal treatment markets [3]. MUSE Commercial Potential - The MUSE device facilitates minimally invasive treatment for GERD patients. SciSparc intends to leverage Xylo's previous commercialization success in Greater China to penetrate North America, Europe, and Latin America. Xylo had previously secured a licensing deal in 2019 with a Shanghai-based distributor, receiving $3 million upfront, which SciSparc plans to replicate through exclusive regional partnerships [4]. Share-Based Consideration Structure - Under the terms of the acquisition, SciSparc will issue equity equal to 19.99% of its outstanding shares upon closing, with the option to substitute part or all of that with pre-funded warrants. This acquisition grants SciSparc direct ownership of the technology and commercialization rights, potentially supporting future licensing revenue and enhancing its diversification strategy [5]. Price Action - Following the announcement, SciSparc shares increased by 29.10%, reaching $3.15, while the stock is near its 52-week low of $1.75 [6].